BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 38846954)

  • 1. CLEC7A regulates M2 macrophages to suppress the immune microenvironment and implies poorer prognosis of glioma.
    Wang J; Li X; Wang K; Li K; Gao Y; Xu J; Peng R; Zhang X; Zhang S; Zhou Y; Xu S; Zhang J
    Front Immunol; 2024; 15():1361351. PubMed ID: 38846954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PDIA5 is Correlated With Immune Infiltration and Predicts Poor Prognosis in Gliomas.
    Zhang H; He J; Dai Z; Wang Z; Liang X; He F; Xia Z; Feng S; Cao H; Zhang L; Cheng Q
    Front Immunol; 2021; 12():628966. PubMed ID: 33664747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Orphan nuclear receptor TLX promotes immunosuppression via its transcriptional activation of PD-L1 in glioma.
    Zhou J; Pei X; Yang Y; Wang Z; Gao W; Ye R; Zhang X; Liu J; Liu Z; Yang X; Tao J; Gu C; Hu W; Chan FL; Li X; Mao J; Wu D
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33858847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Siglec15 is a prognostic indicator and a potential tumor-related macrophage regulator that is involved in the suppressive immunomicroenvironment in gliomas.
    Wang J; Xu L; Ding Q; Li X; Wang K; Xu S; Liu B
    Front Immunol; 2023; 14():1065062. PubMed ID: 37325664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ITGB2 as a prognostic indicator and a predictive marker for immunotherapy in gliomas.
    Xu H; Zhang A; Han X; Li Y; Zhang Z; Song L; Wang W; Lou M
    Cancer Immunol Immunother; 2022 Mar; 71(3):645-660. PubMed ID: 34313821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IL4I1 in M2-like macrophage promotes glioma progression and is a promising target for immunotherapy.
    Ye F; Wang L; Li Y; Dong C; Zhou L; Xu J
    Front Immunol; 2023; 14():1338244. PubMed ID: 38250074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon regulatory factor transcript levels correlate with clinical outcomes in human glioma.
    Lei J; Zhou MH; Zhang FC; Wu K; Liu SW; Niu HQ
    Aging (Albany NY); 2021 Apr; 13(8):12086-12098. PubMed ID: 33902005
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Gao X; Liu Y; Hong S; Yang H; Guan B; Ma X
    J Integr Neurosci; 2023 Aug; 22(5):135. PubMed ID: 37735118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer-associated fibroblast-associated gene IGFBP2 promotes glioma progression through induction of M2 macrophage polarization.
    Zhang X; Sun X; Guo C; Li J; Liang G
    Am J Physiol Cell Physiol; 2024 Jan; 326(1):C252-C268. PubMed ID: 37982173
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Qu S; Liu J; Wang H
    Front Immunol; 2021; 12():648416. PubMed ID: 33889156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systematic identification, development, and validation of prognostic biomarkers involving the tumor-immune microenvironment for glioblastoma.
    Zhao B; Wang Y; Wang Y; Chen W; Liu PH; Kong Z; Dai C; Wang Y; Ma W
    J Cell Physiol; 2021 Jan; 236(1):507-522. PubMed ID: 32572951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune cell gene expression signatures in diffuse glioma are associated with IDH mutation status, patient outcome and malignant cell state, and highlight the importance of specific cell subsets in glioma biology.
    Mehani B; Asanigari S; Chung HJ; Dazelle K; Singh A; Hannenhalli S; Aldape K
    Acta Neuropathol Commun; 2022 Feb; 10(1):19. PubMed ID: 35144680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevated expression of DOK3 indicates high suppressive immune cell infiltration and unfavorable prognosis of gliomas.
    Liu X; Chen F; Li W
    Int Immunopharmacol; 2020 Jun; 83():106400. PubMed ID: 32193105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. B2M overexpression correlates with malignancy and immune signatures in human gliomas.
    Zhang H; Cui B; Zhou Y; Wang X; Wu W; Wang Z; Dai Z; Cheng Q; Yang K
    Sci Rep; 2021 Mar; 11(1):5045. PubMed ID: 33658560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor Purity as an Underlying Key Factor in Glioma.
    Zhang C; Cheng W; Ren X; Wang Z; Liu X; Li G; Han S; Jiang T; Wu A
    Clin Cancer Res; 2017 Oct; 23(20):6279-6291. PubMed ID: 28754819
    [No Abstract]   [Full Text] [Related]  

  • 16.
    Ma W; Zhang K; Bao Z; Jiang T; Zhang Y
    Front Immunol; 2021; 12():659659. PubMed ID: 33936093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TNFSF13 Is a Novel Onco-Inflammatory Marker and Correlates With Immune Infiltration in Gliomas.
    Chen R; Wang X; Dai Z; Wang Z; Wu W; Hu Z; Zhang X; Liu Z; Zhang H; Cheng Q
    Front Immunol; 2021; 12():713757. PubMed ID: 34712225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ferroptosis-related gene signature correlates with the tumor immune features and predicts the prognosis of glioma patients.
    Hu Y; Tu Z; Lei K; Huang K; Zhu X
    Biosci Rep; 2021 Dec; 41(12):. PubMed ID: 34726238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ABCD3 is a prognostic biomarker for glioma and associated with immune infiltration: A study based on oncolysis of gliomas.
    Li J; Zhang Y; Qu Z; Ding R; Yin X
    Front Cell Infect Microbiol; 2022; 12():956801. PubMed ID: 35959373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diverse Macrophages Constituted the Glioma Microenvironment and Influenced by PTEN Status.
    Zhou F; Shi Q; Fan X; Yu R; Wu Z; Wang B; Tian W; Yu T; Pan M; You Y; Wang Y
    Front Immunol; 2022; 13():841404. PubMed ID: 35265085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.